Department of Laboratory Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Front Immunol. 2024 Sep 4;15:1453774. doi: 10.3389/fimmu.2024.1453774. eCollection 2024.
Previous studies have demonstrated that genetic alterations governing epigenetic processes frequently drive tumor development and that modifications in RNA may contribute to these alterations. In the 1970s, researchers discovered that N6-methyladenosine (mA) is the most prevalent form of RNA modification in advanced eukaryotic messenger RNA (mRNA) and noncoding RNA (ncRNA). This modification is involved in nearly all stages of the RNA life cycle. MA modification is regulated by enzymes known as mA methyltransferases (writers) and demethylases (erasers). Numerous studies have indicated that mA modification can impact cancer progression by regulating cancer-related biological functions. Tumor angiogenesis, an important and unregulated process, plays a pivotal role in tumor initiation, growth, and metastasis. The interaction between mA and ncRNAs is widely recognized as a significant factor in proliferation and angiogenesis. Therefore, this article provides a comprehensive review of the regulatory mechanisms underlying mA RNA modifications and ncRNAs in tumor angiogenesis, as well as the latest advancements in molecular targeted therapy. The aim of this study is to offer novel insights for clinical tumor therapy.
先前的研究表明，控制表观遗传过程的遗传改变常常驱动肿瘤的发展，并且 RNA 的修饰可能促成这些改变。在 20 世纪 70 年代，研究人员发现 N6-甲基腺苷 (mA) 是高级真核信使 RNA (mRNA) 和非编码 RNA (ncRNA) 中最普遍的 RNA 修饰形式。这种修饰几乎涉及 RNA 生命周期的所有阶段。mA 修饰受称为 mA 甲基转移酶（“书写器”）和去甲基化酶（“橡皮擦”）的酶调节。大量研究表明，mA 修饰可以通过调节与癌症相关的生物学功能来影响癌症的进展。肿瘤血管生成是一个重要的、不受调节的过程，在肿瘤的发生、生长和转移中起着关键作用。mA 和 ncRNAs 之间的相互作用被广泛认为是增殖和血管生成的重要因素。因此，本文全面综述了 mA RNA 修饰和 ncRNAs 在肿瘤血管生成中的调控机制，以及分子靶向治疗的最新进展。本研究旨在为临床肿瘤治疗提供新的见解。
